Yukoh Yoshida President Senju Pharmaceutical Co., Ltd. 5-8, Hiranomachi 2-chome Chuo-ku, Osaka, 541-0046 Japan Dear Mr. Yoshida:Ista Pharmaceuticals Inc • December 17th, 2009 • In vitro & in vivo diagnostic substances
In connection with our recent letter regarding changing the terms and conditions of the Bromfenac License Agreement dated March 7, 2002, and amended August 13, 2002 and May 31, 2006, this letter is to further document our mutual agreement to the following additional change.
LOAN MODIFICATION AGREEMENTLoan Modification Agreement • December 17th, 2009 • Ista Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This Loan Modification Agreement is entered into as of December 16, 2009, by and between ISTA PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”) and SILICON VALLEY BANK (“Bank”).
